AstraZeneca PLC header image

AstraZeneca PLC

AZN

Equity

ISIN GB0009895292 / Valor 982352

LSE London Stock Exchange, SETS (2024-09-16)

GBP 120.16+0.74%

AstraZeneca PLC
UMushroom community rating:

4.29 8 votes No rating yet

NegativeNeutralPositive

About company

AstraZeneca PLC is a global pharmaceutical company with a focus on the discovery, development, and commercialization of prescription medicines across various therapy areas. The company is science-led and patient-focused, aiming to address unmet medical needs by bringing innovative medicines to market. AstraZeneca operates in key therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology, with a growing pipeline in rare diseases. Its business strategy emphasizes growth through innovation, leveraging advanced therapeutic modalities and engaging in strategic partnerships to enhance healthcare outcomes. AstraZeneca's commitment to healthcare extends to improving access to its medicines globally, ensuring it plays a significant role in transforming the future of healthcare.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

9.84%1Y

47.6%3Y

75.8%5Y

Performance

21.3%1Y

23.0%3Y

24.9%5Y

Volatility

246031 M

Market cap (USD)

787,440

Daily traded volume (Shares)

120.6 / 119.66

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.29

8 votes

Performance:

4.36

Innovation:

4.36

Society:

3.91

Nature:

3.36

Lou Charlotte Wehrli

Switzerland, 01 Nov 2023

Innovation in healthcare and rare diseases is so important - AstraZeneca is doing a good job at that

Tonia Zimmermann

Switzerland, 01 Nov 2023

One of the few names profiting from the pandemic without giving up all the gains. Well diversified portfolio and strategy.

Laura Bischofberger

Switzerland, 01 Nov 2023

Interessanter Deal mit Cellectis

EQUITIES OF THE SAME SECTOR

AstraZeneca PLC

AstraZeneca PLC Valor: 163523

Annual Return

-50%0%+50%

Risk level

110

0.98%USD 79.04

Boiron SA

Boiron SA Valor: 487646

Annual Return

-50%0%+50%

Risk level

110

0.31%EUR 32.30

Calliditas Therapeutics AB

Calliditas Therapeutics AB Valor: 42290712

Annual Return

-50%0%+50%

Risk level

110

0.10%SEK 206.40

OKYO Pharma Limited

OKYO Pharma Limited Valor: 127195533

Annual Return

-50%0%+50%

Risk level

110

1.46%USD 1.04

Sanofi SA

Sanofi SA Valor: 1447201

Annual Return

-50%0%+50%

Risk level

110

0.35%USD 57.33

Bausch Health Companies Inc

Bausch Health Companies Inc Valor: 42260834

Annual Return

-50%0%+50%

Risk level

110

10.76%USD 7.00

Biogen Inc

Biogen Inc Valor: 1720684

Annual Return

-50%0%+50%

Risk level

110

2.02%USD 199.58

Illumina Inc

Illumina Inc Valor: 1111080

Annual Return

-50%0%+50%

Risk level

110

0.26%USD 129.52

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc Valor: 1806798

Annual Return

-50%0%+50%

Risk level

110

1.92%USD 270.37

Align Technology Inc

Align Technology Inc Valor: 1159441

Annual Return

-50%0%+50%

Risk level

110

2.39%USD 249.56

SIX

FactSet

Clearbit

Logos provided by Clearbit